Details

Autor(en) / Beteiligte

• Sukor, Norlela
• Sunthornyothin, Sarat
• Thang, Tran Viet
• Tarigan, Tri Juli
• Mercado-Asis, Leilani B
• Sum, Satha
• Aung, Moe Wint
• Yong, Alice M L
• Tedjo, Tania
• Villa, Michael
• Khaing, Nang Ei Ei
• Azizan, Elena Aisha
• Kang, Waye Hann
• Lim, Vivien
• Teo, Ada E D
• Zhang, Meifen
• Tran, Hieu
• Puar, Troy H

Titel

Healthcare Challenges in the Management of Primary Aldosteronism in Southeast Asia

Ist Teil von

• The journal of clinical endocrinology and metabolism, 2024-01

Ort / Verlag

United States

Erscheinungsjahr

2024

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• While guidelines have been formulated for the management of primary aldosteronism (PA), following these recommendations may be challenging in developing countries with limited healthcare access. Hence, we aimed to assess the availability and affordability of healthcare resources for managing PA in the Association of Southeast Asian Nations (ASEAN) region, which includes low-middle-income countries. We instituted a questionnaire-based survey to specialists managing PA, assessing the availability and affordability of investigations and treatment. Population and income status data were taken from the national census and registries. Nine ASEAN country members (48 respondents) participated. While screening with aldosterone-renin-ratio is performed in all countries, confirmatory testing is routinely performed in only six countries due to lack of facilities and local assays, and cost constraint. Assays are only locally available in four countries, and some centers have a test turnaround time exceeding three weeks. In seven countries (combined population of 442 million), adrenal vein sampling (AVS) is not routinely performed due to insufficient radiological facilities or trained personnel, and cost constraint. Most patients have access to adrenalectomy and medications. In six countries, the cost of AVS and adrenalectomy combined is >30% of its annual gross domestic product per capita. While most patients had access to spironolactone, it was not universally affordable. Large populations currently do not have access to the healthcare resources required for the optimal management of PA. Greater efforts are required to improve healthcare access and affordability. Future guideline revisions for PA may need to consider these limitations.